Tumor progression locus 2 (TPL2), a serine/threonine kinase, has been regarded as a potentially interesting target for the treatment of various diseases with an inflammatory component. However, the function of TPL2 in regulating hepatocyte metabolism and liver inflammation during the progression of nonalcoholic fatty liver disease (NAFLD) is poorly understood. Here, we report that TPL2 protein expression was significantly increased in fatty liver from diverse species, including humans, monkeys, and mice. Further investigations revealed that compared to wild-type (WT) littermates, hepatocytespecific TPL2 knockout (HKO) mice exhibited improved lipid and glucose imbalance, reserved insulin sensitivity, and alleviated inflammation in response to high-fat diet (HFD) feeding. Overexpression of TPL2 in hepatocytes led to the opposite phenotype. Regarding the mechanism, we found that mitogen-activated protein kinase kinase 7 (MKK7) was the specific substrate of TPL2 for c-Jun N-terminal kinase (JNK) activation. TPL2-MKK7-JNK signaling in hepatocytes represents a promising drugable target for treating NAFLD and associated metabolic disorders. Conclusion: In hepatocytes, TPL2 acts as a key mediator that promotes both liver and systemic metabolic disturbances by specifically increasing MKK7-JNK activation. (
Xiao-Dong Zhang, 1 and Zhi-Gang She [2] [3] [4] [5] Tumor progression locus 2 (TPL2), a serine/threonine kinase, has been regarded as a potentially interesting target for the treatment of various diseases with an inflammatory component. However, the function of TPL2 in regulating hepatocyte metabolism and liver inflammation during the progression of nonalcoholic fatty liver disease (NAFLD) is poorly understood. Here, we report that TPL2 protein expression was significantly increased in fatty liver from diverse species, including humans, monkeys, and mice. Further investigations revealed that compared to wild-type (WT) littermates, hepatocytespecific TPL2 knockout (HKO) mice exhibited improved lipid and glucose imbalance, reserved insulin sensitivity, and alleviated inflammation in response to high-fat diet (HFD) feeding. Overexpression of TPL2 in hepatocytes led to the opposite phenotype. Regarding the mechanism, we found that mitogen-activated protein kinase kinase 7 (MKK7) was the specific substrate of TPL2 for c-Jun N-terminal kinase (JNK) activation. TPL2-MKK7-JNK signaling in hepatocytes represents a promising drugable target for treating NAFLD and associated metabolic disorders. Conclusion: In hepatocytes, TPL2 acts as a key mediator that promotes both liver and systemic metabolic disturbances by specifically increasing MKK7-JNK activation. ( N onalcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease in the world, affecting up to 30% of the adult population and 70-80% of individuals who have obesity and diabetes.
(1) NAFLD encompasses a disease spectrum, ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), a progressive pathology leading to cirrhosis and other end-stage liver diseases. (2) Characterized by severe steatosis, cellular injury, inflammation and/or fibrosis in the liver, NASH is commonly accompanied by systematic metabolic disorders, like obesity and insulin resistance Abbreviations: aa, amino acid; AKT, protein kinase B; Alb, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; ASK1, apoptosis signal-regulating kinase 1; AST, aspartate aminotransferase; AUC, area under the curve; ERK, extracellular signal-regulated kinase; FBG, fasting blood glucose; FINS, fasting serum insulin; FOXO1, forkhead box protein O1; G6Pase, glucose-6-phosphatase; GSK3b, glycogen synthase kinase 3b; GTT, glucose tolerance test; HA, hemagglutinin; HDL-C, high-density lipoprotein cholesterol; H&E, hematoxylin and eosin; HFD, high-fat diet; HKO, hepatocyte-specific TPL2 knockout; HOMA-IR, homeostatic model assessment IR index; HS, hepatic steatosis; HTG, hepatocyte-specific TPL2 transgenic; iAUC, incremental area under the curve; IjBa, inhibitor of kappa B alpha; IKKb, inhibitor of nuclear factor kappa-B kinase subunit beta; IL, interleukin; IP, immunoprecipitation; IR, insulin resistance; IRS1, insulin receptor substrate 1; ITT, insulin tolerance test; JNK, c-Jun N-terminal kinase; LDL-C, low-density lipoprotein cholesterol; LS, liver steatosis; LW, liver weight; LW/BW, liver weight/body weight; MAPK, mitogen-activated protein kinase; MCD, methionine-and choline-deficient diet; MCP-1, monocyte chemoattractant protein 1; MEK, MAPK kinase; MKK7, mitogen-activated protein kinase kinase 7; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; NC, normal chow diet; NEFA, nonesterified fatty acid; NF-jB, nuclear factor kappa B; ORO, Oil Red O; PA, palmitate; PAS, Periodic acid-Schiff; PEPCK, phosphoenol pyruvate carboxylase; TC, total cholesterol; TG, triglyceride; TNF-a, tumor necrosis factor alpha; TPL2, tumor progression locus 2; WT, wild type.
(IR).
(3) However, the treatment options for NASH are limited. (4) Thus, in-depth studies are needed to identify the key regulators and molecular targets for therapeutic development.
Tumor progression locus 2 (TPL2), also known as COT and MAP3K8, is a mitogen-activated protein kinase (MAPK) kinase kinase (MAP3K) that plays a key role in innate and adaptive immunity and influences inflammatory processes by modulating the function of different cell types. (5) (6) (7) (8) Accumulating evidence indicates that TPL2 is a drugable target in several inflammatory disease, for example, atherosclerosis, (9) cancer, (10) and acetaminophen-induced liver sterile inflammation. (11) Chronic low-grade inflammation is closely related to and may underlie the etiology and progression of NAFLD and its complications. (12) The role of TPL2 in these metabolic diseases has attracted considerable attention. TPL2 ablation attenuates inflammation and IR. (13) TPL2 is up-regulated in adipose tissue in obesity and mediates the deleterious effects of inflammatory cytokines on adipocyte function. (14) In contrast, two other studies reported that TPL2 plays no significant role in obesityassociated metabolic dysfunction. (15, 16) These inconsistent results might originate from the experiments performed on TPL2 whole-null knockout mice and mainly focus on adipose tissue. However, the function of TPL2 in hepatocytes during the progression of NAFLD and concomitant metabolic disturbances remains largely unknown. One recent study revealed that TPL2 promoted diethylnitrosamine-initiated, NAFLD-associated hepatocellular carcinoma (HCC) development through its proinflammatory effect, which supports TPL2 as a molecular target for HCC prevention. (17) In our preliminary experiments, we observed significantly increased TPL2 expression in fatty liver from various species, including humans, monkeys, and mice. These notable results prompted us to further investigate the potential role of TPL2 in hepatocytes and decipher its underlying mechanism in regulating NAFLD and metabolic disorders.
In our present study, hepatocyte-specific TPL2 knockout (HKO) and TPL2 transgenic mice were generated and subjected to high-fat diet (HFD) feeding to evaluate the effects of TPL2 on liver and systemic metabolic disorders. We identified hepatocyte TPL2 as a key promoter of hepatic steatosis (HS), IR, and inflammatory response.
Materials and Methods

HUMAN AND MONKEY LIVER SAMPLES
Human and monkey liver samples were obtained as described, and corresponding clinical information has been reported on. (18) All procedures that involved human samples were approved by the ethics committee of Renmin Hospital of Wuhan University (Wuhan, China) and adhered to the principles of the Declaration of Helsinki. 
ANIMALS AND TREATMENT
PRIMARY HEPATOCYTE ISOLATION AND CULTURE
Primary hepatocytes were isolated from 6-to 8-week-old mice. Briefly, after being anesthetized, mice were perfused through the portal vein with Perfusion Medium (17701-038; Life Technologies, Carlsbad, CA) and then perfused with Liver Digest Medium (17703-034; Life Technologies). After digestion, liver was excised, minced and filtered through a 100 lm steel mesh (Life Technologies). Hepatocytes were separated by centrifugation at 50g for 1 minute for two times. The obtained hepatocytes were resuspended in Dulbecco's modified Eagle's medium and seeded in the plates. Palmitate (PA; 0.25 mM; Sigma-Aldrich) was added to the medium for 24 hours to establish the in vitro model of lipid accumulation in hepatocytes.
WESTERN BLOTTING ANALYSIS
For western blotting analysis, total protein was isolated from tissue or cell samples using radioimmunoprecipitation assay lysis buffer and quantified. Then, protein samples were separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes, which were blocked with 5% skim milk for 90 minutes. Then, membranes were incubated with primary antibodies at 48C overnight, followed by incubation with the corresponding secondary antibodies. All the antibodies used in this study are listed in Supporting Table S1 .
GENERATION OF GENETICALLY MODIFIED MICE
TPL2
flox/flox (TPL2-flox) mice were created using the CRISPR/Cas9 system. The fourth exon was flanked by two loxP sites, and two single-guide RNAs (gRNA1 and gRNA2) targeting TPL2 introns 3 and 4 were designed. The donor plasmid contained exon 4 flanked by two loxP sites and the two homology arms were used as the homologous recombination-mediated repairing template. A simple schematic is shown in Supporting Fig. S1 . The donor plasmid, gRNA1 and gRNA2, and Cas9 mRNAs were coinjected into onecell-stage embryos (C57BL/6 background). The resulting mice were screened using the PCR primers, TPL2-P1 to TPL2-P6, which are provided in Supporting Table S2 . Hepatocyte-specific TPL2 knockout (TPL2-HKO) mice were generated by mating TPL2-flox mice with albumin (Alb)-Cre mice (Jackson Laboratory, Bar Harbor, ME).
Full-length mouse TPL2 complementary DNA (cDNA) was cloned downstream of the Alb promoter. Hepatocyte-specific TPL2 transgenic mice (TPL2-HTG) were then produced by microinjection of the Alb-TPL2 construct into fertilized mouse embryos (C57BL/6 background). ob/ob mice were provided by Jackson Laboratory.
MOUSE METABOLIC ASSAYS
Mouse metabolic assays were performed as described. (19) Briefly, body weight, fasting blood glucose (FBG) levels, and fasting serum insulin (FINS) levels were determined in mice every 2 weeks. Based on FBG and FINS results, the homeostatic model assessment IR index (HOMA-IR) was calculated. To perform glucose tolerance tests (GTTs) and insulin tolerance tests (ITTs), mice were fasted for 16 or 6 hours, then intraperitoneally injected with 1 g/kg of glucose or 0.75 U/kg of insulin, respectively. Blood glucose levels were measured at 0, 15, 30, 60, and 120 minutes after injection. Areas under the curve (AUCs) are given as the incremental area under the curve (iAUC; area above baseline), calculated by the conventional trapezoid rule.
HISTOLOGICAL ANALYSIS
Liver sections were embedded in paraffin and then stained with hematoxylin and eosin (H&E) to visualize the pattern of lipid accumulation and inflammatory status. Lipid droplet accumulation in liver was visualized using Oil Red O (ORO) staining of frozen liver sections that were prepared in Tissue-Tek optimal cutting temperature compound. Periodic acid-Schiff (PAS) staining was performed using paraffin-embedded liver sections as described (20) to determine tissue glycogen content. Histological features of tissues were observed and imaged using a light microscope (Olympus, Tokyo, Japan).
CELL LINES AND ORO STAINING IN L-02 CELLS
All cell lines used in this study, including the normal human hepatocyte cell line, L-02, and HEK293T cells, were purchased from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). Mycoplasma contamination was checked at least once per month. None of the cell lines were authenticated in-house by short tandem repeat DNA profiling. L-02 cells were stained in a 0.3% ORO working solution for 30 minutes to examine intracellular lipid accumulation.
MOUSE SERUM CYTOKINE AND HEPATIC LIPID ANALYSES
Serum cytokine, triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and nonesterified fatty acid (NEFA) levels and hepatic TG, TC, and NEFA levels were determined using the enzyme-linked immunosorbent assay kits listed in Supporting Table S3 .
LIVER FUNCTION ASSAY
Liver function was evaluated in animals by determining serum concentrations of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) using an ADVIA 2400 Chemistry System Analyzer (Siemens, Tarrytown, NY) according to the manufacturer's instructions.
REAL-TIME QUANTITATIVE PCR ANALYSIS
For real-time quantitative PCR (qPCR) assays, total RNA was isolated and then reverse transcribed. SYBR Green (04887352001; Roche) was used to detect the PCR amplification products. mRNA expression levels of target genes were normalized to b-actin expression. The primer pairs used in this study are listed in Supporting Table S4 .
PLASMID CONSTRUCTS
Plasmids encoding full-length and truncated hemagglutinin (HA)-TPL2 were constructed by cloning the indicated coding regions of mouse TPL2 cDNA into pcDNA5-HA-C1. Furthermore, dominantnegative TPL2 (HA-TPL2 [D270A]) was constructed as reported. (21) Full-length and truncated Flag-MKK7 (mitogen-activated protein kinase kinase 7) were obtained by cloning the indicated MKK7 into pcDNA5-Flag-C1 vector. Primers used for plasmid construction are listed in Supporting Table S5 .
IMMUNOPRECIPITATION ASSAY
For immunoprecipitation (IP) assays, cultured HEK 293T cells were cotransfected with the indicated plasmids for 24 hours and lysed. Cell homogenates were incubated with constant agitation and then centrifuged. For each IP, 500 lL of the sample was incubated with 10 lL of Protein A/G-agarose beads (11719394001, 11719386001; Roche) and 1 lg of the indicated antibody on a rocking platform (overnight at 48C). Finally, IPs were washed five to six times with cold IP buffer before adding 13 loading buffer. Cell lysates and IPs were immunoblotted with the indicated primary antibodies and corresponding secondary antibodies.
ADENOVIRUS VECTOR CONSTRUCTION AND INFECTION
Knockdown or overexpression cassettes were placed into pShuttle vector. The resulting plasmids were recombined with the pAdEasy backbone vector. Adenovirus was packaged in HEK293 cells and plaquepurified. Primary hepatocytes were infected with adenoviruses in diluted medium at a multiplicity of infection of 50. Mice were infected with indicated adenovirus (5 3 10 9 pfu) through tail vein injection. Detailed information is provided in the Supporting Methods.
STATISTICAL ANALYSIS
Statistical analysis was performed as described. (22) In brief, all statistical analyses were performed using SPSS software (version 19.0). For data shown on Gaussian distribution, parametric statistical analysis was performed using the two-tailed Student t test for two groups. For data sets with skewed distribution, nonparametric statistical analysis was performed using the Mann-Whitney U test for two groups. Two-way analysis of variance (ANOVA) without repeated measures was applied for multiple comparisons with two independent variables. After confirming that the interaction effect was statistically significant, one-way ANOVA was applied for inspecting simple effects followed by Bonferroni post-hoc analysis for data meeting homogeneity of variance or with Tamhane's T2 analysis for data of heteroscedasticity. Only in cases in which the global null hypothesis was rejected was pairwise comparison then performed. All values are presented as the mean 6 SD. P values were specified as follows:
# P < 0.05; ## P < 0.01; *P < 0.05; **P < 0.01.
Results
HEPATIC TPL2 EXPRESSION IS UP-REGULATED IN NAFLD-RELATED PATHOLOGIES
Deregulation of TPL2 expression could reflect its potential involvement in certain pathologies, such as inflammatory diseases, type 1 diabetes, and cancer. (13, 23, 24) We compared hepatic TPL2 expression in normal and NAFLD-related pathologies in a series of pilot studies. Western blotting revealed that TPL2 expression was much higher in human simple steatosis and NASH liver samples than in normal human liver samples (Fig. 1A) . The same pattern was observed in monkey simple steatosis and NASH liver samples compared to normal samples (Fig. 1B) . In the mouse NAFLD model, TPL2 expression was significantly up-regulated after HFD feeding for 12 weeks or MCD feeding for 4 weeks (Fig. 1C,D) . Moreover, TPL2 expression was significantly higher in genetically obese (ob/ob) mice than in lean mice (Fig. 1E) . To confirm the expression of TPL2 in vitro, primary hepatocytes were isolated from wild-type (WT) mice and challenged with PA, a well-established inducer of lipid accumulation in hepatocytes. (25, 26) Our data showed that PA stimulation led to a striking increase in TPL2 expression in primary hepatocytes (Fig. 1F ). However, the expression level of TPL2 mRNA was significantly changed, with no change of the protein level of phosphorylated TPL2 compared to the NC group, suggesting that HFD primarily increased TPL2 expression at transcription level without change its intrinsic activity (Supporting Fig. S2A,B) . Collectively, the observed TPL2-expression profile indicates the possible involvement of TPL2 in the development of HS.
DELETION OF TPL2 IN HEPATOCYTES AMELIORATES HFD-INDUCED OBESITY, IR, AND LIVER STEATOSIS
Obesity and IR are key phenotypic characteristics of NAFLD. Therefore, to investigate the role of hepatic TPL2 in HFD-induced obesity and IR, we first generated HKO mice. Western blotting analysis revealed that TPL2 expression was significantly decreased in liver, but unchanged in other organs, of HKO mice compared to control (Flox) mice ( Fig. 2A) . With HFD feeding, body weights, FBG levels, FINS level, and HOMA-IR index of HKO and Flox mice were markedly increased compared to NC-fed controls. However, levels of FBG, FINS, and HOMA-IR index in HKO mice were much lower than those in Flox littermates from 2 to 12 weeks of HFD administration ( Fig. 2B-E) . Notably, there were no obvious differences in body weight or FBG or FINS levels between NC-fed Flox and HKO mice (Fig. 2B-E) . HKO mice subjected to an HFD improved glucose tolerance compared to control mice, as revealed by GTT results (Fig.  2F) . Although the iAUC showed no significant differences in ITT assay, the glucose level of HFD-fed HKO mice was improved throughout 0-120 minutes after insulin injection (Fig. 2G ). In accord with this phenotype, HKO mice exhibited lower expression levels of gluconeogenic genes (phosphoenol pyruvate carboxylase [PEPCK] and glucose-6-phosphatase [G6Pase]); Fig. 2H ) and higher glycogen content in liver (Fig. 2I) . In addition, the active levels of crucial insulin-related signaling elements, including insulin receptor substrate 1 (IRS1)/protein kinase B AKT/glycogen synthase kinase 3b (GSK3b)/forkhead box protein O1 (FOXO1), were assessed in liver, muscle, and adipose tissues of Flox and HKO mice; the phosphorylated levels of these components were markedly increased in liver (Fig. 2J ), but not in muscle and adipose tissues (Supporting Fig. S3A,B) , of HFD-fed HKO mice compared to HFD-fed Flox controls.
In addition to obesity and IR, lipid accumulation in the liver is a key characteristic of NAFLD, and it is always accompanied by a severe hepatic inflammatory Target protein levels were normalized to b-actin levels. In (F) and (G), the right panel is the iAUC. Data are presented as the mean 6 SD; ## P < 0.01, TPL2-Flox HFD group versus the TPL2-Flox NC group; *P < 0.05; **P < 0.01, TPL2-HKO HFD group versus the TPL2-Flox HFD group. Abbreviation: n.s., not significant. response. Liver weight (LW) and liver weight/body weight (LW/BW) index increased in HKO and Flox mice after HFD administration for 12 continuous weeks, but HKO mice exhibited less-pronounced gains than Flox mice (Fig. 3A ). There were no such phenotypic differences in response to the NC diet. Accordingly, HFD-fed HKO mice exhibited strikingly lower lipid accumulation and lipid content in liver, as observed in H&E-and ORO-stained liver sections (Fig. 3B ) and in analyses of hepatic TG, TC, and NEFA levels (Fig. 3C) . Similarly, less lipid accumulation was also observed in PA-treated primary hepatic cells in which TPL2 was knocked down by AdshTPL2 infection (Fig. 3D) . Moreover, in accord with ameliorated liver steatosis (LS), HKO mice exhibited lower expression levels of genes involved in cholesterol synthesis (HMGCR), fatty acid uptake (FATP1, FABP1, and CD36), and fatty acid synthesis (SREBP-1c, FAS, ACCa, and PPARc) and higher expression levels of genes responsible for cholesterol efflux (CYP7A1 and ABCG1) and fatty acid b-oxidation (PPARa, CPT-1a, ACOX-1, PDK4, MCAD, and UCP2) in HKO mice compared to Flox controls after HFD feeding for 12 weeks (Fig. 3E ). In addition, serum TG, TC, and LDL-C levels were significantly lower in HKO mice than in their littermate controls after HFD feeding, whereas serum HDL-C level was significantly higher in HKO mice after HFD feeding (Fig. 3F ). In accord with the lower lipid accumulation in liver of HFD-fed TPL2 HKO mice, these mice exhibited better liver function, as evidenced by the lower serum ALT, AST, and ALP levels compared to their littermate controls fed a HFD for 12 weeks (Fig. 3G) .
Chronic inflammation plays a critical role in the development of obesity-related metabolic diseases, (27) and TPL2 is an important mediator of nuclear factor kappa B (NF-jB) and MAPK signaling and the related inflammatory responses. (17, 28) These interactions suggest the possibility of a close relationship between inflammatory regulation by TPL2 and its influence on hepatic steatosis (HS). TPL2-HKO mice had higher serum levels of the anti-inflammatory factor, interleukin (IL)-10, and lower serum levels of proinflammatory markers, including tumor necrosis factor alpha (TNF-a), IL-1b, monocyte chemoattractant protein 1 (MCP-1), and IL-6, compared to TPL2-flox controls after 12 weeks on an HFD (Fig.  3H) . Similarly, consistent results were obtained upon analysis of mRNA levels of these cytokines (Fig. 3I) . Western blotting analyses revealed that loss of TPL2 in hepatocytes resulted in significantly decreased phosphorylation of inhibitor of nuclear factor kappa-B kinase subunit beta (IKKb) and increased phosphorylation of inhibitor of kappa B alpha (IjBa) in HKO mice upon HFD administration (Fig. 3J) . Taken together, these results strongly suggest that TPL2 deletion in hepatocytes ameliorates HFD-induced obesity, IR, LS, and inflammation.
HEPATOCYTE-SPECIFIC TPL2 OVEREXPRESSION AGGRAVATES HFD-INDUCED OBESITY, IR, AND LS
Ameliorated obesity, IR, LS, and inflammation in HKO mice prompted us to further address whether TPL2 overexpression in the liver exacerbates HFDinduced metabolic disorders. Therefore, we generated hepatocyte-specific TPL2 transgenic (HTG) mice for subsequent experiments (Fig. 4A) . Levels of FBG, FINS, and HOMA-IR index were significantly higher in HFD-fed HTG mice than in WT mice, although there was no difference between these genotypes on an NC diet (Fig. 4B-E) . Deteriorated glucose tolerance was observed in HFD-fed HTG mice relative to WT mice, as revealed by the GTT results (Fig. 4F ). The glucose level of HFD-fed HTG mice was significantly higher than HFD-fed WT mice throughout 0-120 minutes after insulin injection, although there were no significant differences in iAUC of the ITT assay (Fig.  4G) . Moreover, insulin-related signaling was inhibited, as indicated by increased expression levels of gluconeogenic genes (PEPCK and G6Pase; Fig. 4H ), decreased glycogen content (Fig. 4I) , and decreased phosphorylation of IRS1/AKT/GSK3b/FOXO1 in liver (Fig. 4J ), but not in muscle and adipose tissues (Supporting Fig.  S3C,D) , of HTG mice compared to WT controls after HFD feeding. In addition, LW, LW/BW index (Fig.  4K) , liver lipid accumulation (Fig. 4L) , and liver lipid content (Fig. 4M ) increased substantially in HTG mice compared to WT controls after HFD administration. In addition, greater lipid accumulation was observed in TPL2-overexpressing primary hepatocytes (AdTPL2 infection) than the control group (AdGFP infection) after PA treatment (Fig. 4N) .
In accord with aggravated LS, HTG mice increased the transcription of genes involved in cholesterol synthesis, fatty acid uptake, and fatty acid synthesis and decreased the expression levels of genes responsible for cholesterol efflux and fatty acid b-oxidation compared to WT mice after HFD feeding (Fig. 4O) . In addition, serum TG, TC, and LDL-C levels were significantly higher in HTG mice than in WT mice after HFD feeding, whereas serum HDL-C levels showed the opposite pattern (Fig. 4P) . Furthermore, HTG mice had more-serious liver injury than WT mice after HFD feeding for 12 weeks, as evidenced by serum ALT, AST, and ALP levels (Fig. 4Q) .
In contrast to HKO and Flox mice, HTG mice showed a completely inverse expression pattern of serum and liver inflammatory factors compared to WT mice upon HFD feeding (Fig. 4R,S) . Western blotting analyses revealed that TPL2 overexpression significantly increased the activation of NF-jB signaling in HTG mice compared to their corresponding littermate controls upon HFD administration (Fig. 4T) . Taken together, our loss-and gain-of-function evidence clearly shows that TPL2 regulates the development of HFD-induced HS and inflammation.
TPL2 PROMOTES THE ACTIVATION OF HFD-INDUCED MKK7/c-Jun N-TERMINAL KINASE SIGNALING
To investigate the mechanisms of the MAP3K, TPL2, in regulating HS, we focused on MAPK signaling, which is an important signaling event during the development of NAFLD. (29, 30) HFD administration increased the phosphorylation of extracellular signal-regulated kinase (ERK)1/2, P38, and c-Jun Nterminal kinase (JNK)1/2 in liver of all the indicated groups, but TPL2-induced significant changes were observed in only JNK1/2. Notably, JNK1/2 phosphorylation was dramatically inhibited in HKO mice, but became more pronounced in TPL2-overexpressing mice (Fig. 5A) . Similar to the in vivo findings, the PA-triggered phosphorylation of JNK1/2 was mitigated in AdshTPL2-infected hepatocytes, and the opposite pattern was found in AdTPL2-infected cells compared to AdGFP-infected cells (Fig. 5B) . These in vivo and in vitro results verify the important role of TPL2 in mediating the regulation of JNK1/2 signaling in HFD-induced metabolic disorders.
To further investigate whether signaling upstream of JNK1/2 is also influenced, we examined the activation of MAPK kinase (MEK), MKK3/6, MKK4, and MKK7, which activate downstream JNK1/2. (31) (32) (33) Notably, the HFD-or PA-induced increase in phosphorylated MKK7, but not phosphorylated MEK, MKK3/6, or MKK4, was significantly inhibited by TPL2 deficiency, whereas TPL2 overexpression led to a further increase in MKK7 phosphorylation (Fig.  5C,D) . To explore the mechanism by which TPL2 promotes MKK7-JNK1/2 signaling, we first investigated whether TPL2 could interact with MKK7. We found that MKK7 directly interacted with TPL2 in coimmunoprecipitation (Co-IP) experiments (Fig. 6A) . Mapping assays indicated that the MKK7 1-135 amino acid aa) fragment interacted with TPL2, whereas TPL2 1-145 aa was responsible for the binding to MKK7 (Fig. 6B,C) . Accordingly, TPL2 promoted MKK7 activation in a dose-dependent manner upon PA treatment in vitro, and this pattern was abolished by dominantnegative TPL2 (Fig. 6D) . Furthermore, TPL2-induced MKK7 signaling activation could be blocked by knocking down MKK7 expression in cultured hepatocytes treated with palmitate (Fig. 6E) .
TPL2 PROMOTES HS IN AN MKK7-DEPENDENT MANNER
The influence of TPL2 on the MKK7-JNK1/2 pathway was revealed as above, but whether this axis is required for NAFLD-associated pathologies was undefined. Thus, TPL2 HTG mice and WT mice were infected with AdshMKK7 or AdshRNA, respectively. The increased TPL2 expression and reduced MKK7 expression in liver of the indicated mice after HFD feeding were confirmed by western blotting (Fig. 7A) . In addition, the increase in phosphorylated MKK7 in HFD-fed TPL2 HTG mice was nearly eliminated in TPL2-HTG/AdshMKK7 mice (Fig. 7A) . Inhibition of MKK7 activation strongly suppressed HFD-induced IR in TPL2-HTG/AdshMKK7 mice, as evidenced by the decreased FBG levels, FINS levels, and HOMA-IR index (Fig. 7B-D) . LW, LW/BW index (Fig. 7E) , liver lipid accumulation (Fig. 7F) , liver lipid content (Fig.   7G ), and serum levels of TG, TC, and LDL-C markedly decreased whereas serum HDL-C levels markedly increased (Fig. 7H) upon elimination of activated MKK7 in TPL2-HTG/AdshMKK7 mice. Moreover, serum levels of proinflammatory factors were decreased in TPL2-HTG/AdshMKK7 mice, whereas levels of the anti-inflammatory factor, IL-10, were increased in TPL2-HTG/AdshMKK7 mice after HFD administration (Fig. 7I) . Taken together, these data suggest that TPL2 promotes hepatic IR, steatosis, and inflammation, predominantly in an MKK7-dependent manner.
TPL2 DEPLETION INHIBITS IR, HS, AND INFLAMMATION IN ob/ob MICE
We revealed the role of TPL2 in promoting HFDinduced complications. To confirm whether TPL2 plays a similar role in metabolic disorders triggered by genetic defects, we knocked down TPL2 expression by introducing AdshTPL2 into liver of 8-week-old genetically obese (ob/ob) mice fed an NC diet. TPL2 expression in liver was significantly reduced in AdshTPL2-injected ob/ob mice compared to AdshRNA-injected ob/ob mice (Fig. 8A) . No significant difference was observed in body weight between AdshTPL2-and AdshRNA-injected ob/ob mice fed an NC diet (Fig. 8B ), but FBG (Fig. 8C), FINS (Fig.  8D) , and the HOMA-IR index (Fig. 8E) were significantly reduced in AdshTPL2-injected mice compared to AdshRNA-injected ob/ob mice. AdshTPL2-injected ob/ob mice displayed improved glucose tolerance as revealed by GTT assay (Fig. 8F) . AdshTPL2-injected ob/ob mice kept a significantly lower glucose level than AdshRNA-injected ob/ob mRNA levels of lipid-metabolism-related genes in liver of HFD-fed WT mice and TPL2-HTG mice; n 5 4/group. (P,Q) Serum lipid content (P) and serum ALT, AST, and ALP levels (Q) in WT mice and TPL2-HTG mice fed an NC or HFD for 12 weeks; n 5 16-20/group. (R,S) Serum levels (R) and liver mRNA levels (S) of inflammation factors in WT mice and TPL2-HTG mice fed an HFD for 12 weeks; n 5 4/group. (T) Phosphorylated/total levels of IKKb/NF-jB signaling elements in liver of NC-or HFD-fed WT mice and TPL2-HTG mice; n54/group. Target protein levels were normalized to b-actin levels. In (F) and (G), the right panel is the iAUC. Data are presented as the mean 6 SD; # P < 0.05; ## P < 0.01 TPL2-Flox HFD group versus the TPL2-Flox NC group; *P < 0.05; **P < 0.01 TPL2-HKO HFD group versus the TPL2-Flox HFD group. Abbreviation: n.s., not significant. mice even after exogenous insulin injection, as revealed by ITT analyses (Fig. 8G ). In accord with this phenotype, AdshTPL2-injected ob/ob mice exhibited lower expression levels of gluconeogenic genes (Fig. 8H ) and higher glycogen content (Fig. 8I) compared to control mice. Reduced LW (Fig. 8J) , LW/BW index (Fig .   FIG. 4. (Continued). 8K), liver lipid accumulation (Fig. 8L) , and liver lipid content (Fig. 8M) were observed in AdTPL2-injected ob/ob mice compared to AdshRNA-injected ob/ob mice. These results suggest that TPL2 depletion inhibits genetic-mediated metabolic abnormalities.
Discussion
The serine/threonine kinase, TPL2, plays an important role in innate and adaptive immunity and has emerged as a potentially interesting treatment target in various diseases with an inflammatory component. (6, 8, 9) However, the regulatory effect of TPL2 on the development of NAFLD was largely unknown. Here, using in vivo and in vitro gain-and loss-offunction approaches, we identified TPL2 as a pivotal mediator of the progression of NAFLD and its accompanying metabolic disorders in both dietary and genetic obese mice. Furthermore, we revealed that TPL2 directly induced, and specifically interacts with, MKK7 and sustains JNK1/2 activation to promote liver and systemic metabolic dysfunction.
NAFLD is unquestionably the hepatic manifestation of the metabolic syndrome and represents a huge public health problem. (34) The liver is a central hub of metabolism. Hence, perturbation of the metabolism of lipids, glucose, and other nutrients accounts for systemic metabolic disorder. (35) In this study, hepatocytespecific TPL2 knockout improved the lipid and glucose imbalance induced by long-term HFD feeding. Specifically, TPL2 knockout mice showed decreased mRNA expression of PEPCK and G6pase, two key enzymes for gluconeogenesis, and increased glycogen content in the liver. However, lower lipid accumulation in the liver was observed in TPL2 knockout mice compared to WT controls. Unbalanced lipid storage and utilization results in supraphysiological TG accumulation in hepatocytes, known as HS. (34) TPL2 deficiency depressed the gene expression of molecules responsible for fatty acid synthesis and storage and enhanced the expression of several key genes involved in fatty acid oxidation. IR is a common characteristic of NAFLD. Hepatocytes are insulin-sensitive cells, and IR in the liver results in profound dysregulation of lipid and glucose metabolism. (36) TPL2 knockout mice exhibited improved insulin sensitivity and insulin signaling in the liver, leading to decreased blood glucose and serum lipid content. Past studies have provided contradictory evidence for the role of TPL2 in obesity-induced inflammation and metabolic dysfunction. (13) (14) (15) (16) These phenotypic differences must be attributable to the fact that these experiments were performed on TPL2 universal knockout mice and mainly focus on adipose tissues. In our study, the gain-and loss-of-function of TPL2 specifically in the liver clearly indicated the important role of hepatic TPL2 in promoting the progression of NAFLD and systemic metabolic disorder. Among numerous signaling pathways that are involved in NAFLD, the MAPK pathway has been highlighted for its extensive regulation of inflammatory response and insulin sensitivity and the resulting influence on fatty acid metabolism. (37, 38) Specifically, recent investigations have indicated that overactivation of JNK plays a crucial role in the development of NAFLD/NASH by mediating obesity, inflammation, IR, and HS. (39) (40) (41) Consistently, we previously reported that JNK1/2 is hyperactivated in the liver of individuals with NAFLD and NASH, and this hyperactivation is positively associated with IR, inflammation, and steatosis. (42, 43) Importantly, our group have identified several treatment targets for NAFLD that function by targeting JNK signaling. We identified a short peptide segment derived from CASP8 and FADD-like apoptosis regulator as a critical suppressor of NASH; it acted by blocking the N-terminal dimerization and autophosphorylation of apoptosis signal-regulating kinase 1 (ASK1), leading to the subsequent suppression of JNK1 activity. (22) Similarly, Dickkopf-related protein (DKK) 3, a protein that belongs to the DKK family of Wnt signaling modulators, protects mice against NAFLD progression by inhibiting ASK1 activity and downstream JNK activation. (44) In contrast, hepatic TNF receptor-associated factor 1 promotes LS, inflammation, and IR by increasing activation of ASK1-JNK signaling. (43) Collectively, these findings , and serum inflammation marker levels (I) in the indicated groups following 12 weeks of NC or HFD feeding; n 5 10/group. Data are presented as the mean 6 SD; *P < 0.05; **P < 0.01; Abbreviation: n.s., not significant.
540
541
